Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SS1P: Phase I data

In a dose-escalation Phase I trial in 23 patients with

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE